尼妥珠单抗结合顺铂同步放化疗治疗中晚期鼻咽癌的疗效及安全性  

Efficacy and safety of nimotuzumab combined with cisplatin concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

作　　者：王忠帅[1] WANG Zhong-shuai(Radiotherapy Department,Anshan Cancer Hospital,Anshan 114033,China)

机构地区：[1]鞍山市肿瘤医院放疗科,114033

出　　处：《中国现代药物应用》2021年第20期153-155,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察联合应用尼妥珠单抗与顺铂同步放化疗对中晚期鼻咽癌患者进行治疗的临床效果。方法74例中晚期鼻咽癌患者,按入院顺序分为对照组和观察组,每组37例。对照组应用顺铂同步放化疗,观察组在对照组基础上加用尼妥珠单抗治疗。比较两组治疗效果、不良反应发生情况。结果观察组治疗总有效率86.49%高于对照组的64.86%,差异具有统计学意义(P<0.05)。观察组中性粒细胞减少、红细胞减少、血小板减少、心电图异常、发热、骨髓抑制、消化道反应发生率分别为16.22%、10.81%、5.41%、10.81%、2.70%、10.81%、8.11%,均低于对照组的51.35%、45.95%、27.03%、62.16%、54.05%、40.54%、27.03%,差异均具有统计学意义(P<0.05)。结论联合应用尼妥珠单抗及顺铂同步放化疗对中晚期鼻咽癌患者进行治疗,可获得较为理想的疗效,减少不良反应的发生,安全性高。Objective To observe the clinical effect of nimotuzumab combined with cisplatin concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma.Methods A total of 74 patients with advanced nasopharyngeal carcinoma were divided into control group and observation group according to the order of admission,with 37 cases in each group.The control group was treated with cisplatin concurrent chemoradiotherapy,and the observation group was treated with nimotuzumab on the basis of the control group.The therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment 86.49%in the observation group was higher than 64.86%in the control group,and the difference was statistically significant(P<0.05).The incidence of neutropenia,red blood cell reduction,thrombocytopenia,abnormal electrocardiogram,fever,bone marrow suppression,and digestive tract reaction in the observation group were 16.22%,10.81%,5.41%,10.81%,2.70%,10.81%,8.11%,respectively,which were all lower than 51.35%,45.95%,27.03%,62.16%,54.05%,40.54%,27.03%in the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of nimotuzumab and cisplatin concurrent chemoradiotherapy can obtain ideal efficacy,and reduce the occurrence of adverse reactions with high safety.

关 键 词：中晚期鼻咽癌 尼妥珠单抗 顺铂 放化疗 

分 类 号：R739.63[医药卫生—肿瘤]